

## Type 1 diabetes and technology

22<sup>nd</sup> September 2022

Stuart Little Consultant Diabetologist Stuart.little1@nhs.net

No declarations of interest



## Outline

- Context of current technologies
- Flash glucose monitoring
- Insulin pumps
- Hybrid closed loops
- The future







### Toronto 1922



#### 'Unspeakably wonderful!' Elizabeth Hughes 1907-1981

### Cause of death in diabetes

Marble, Diabetes, 1977: 2 s2: 632

% total mortality



## 24-hour plasma glucose and insulin profiles in healthy individuals



©Elsevier Science. Reproduced with permission from Elsevier Science (The Lancet, 2001, Vol 358, pages 739– 746).

Owens DR et al. Lancet 2001;358:739-746



### Severe Hypoglycaemia: prevalence



## Hypoglycaemia



## **Defective glucose counter regulation**



## Hypoglycaemia Associated Autonomic Failure

Ρ 5 4.4 A 3.9 S Μ 3.3 Α .8 2 **Neuroglycopenic symptoms** Sympathetic neural G 2.2 symptoms **Coma and or seizure** .7 1 U 1 .1 С **Neuronal death (brain** death) 0 56 S Ε







### FreeStyle Libre T1 % Adoption 2019

Primary and Secondary Care Prescribing



### April 10.7%

### FreeStyle Libre T1 % Adoption 2021

Primary and Secondary Care Prescribing

### September 50%



## Freestyle Libre 2





#### **46 countries**

#### >2 million users



## What do the arrows mean?

	Rate of change	How long to change by 1 mmol/l	How much will it change in 30 mins
<b>↑</b>	> 0.11 mmol/l / min	Average 7 mins	At least 3 mmol/l
7	Between 0.11 and 0.06 mmol/I / min	Average 15 mins	2-3 mmol/min
<b>→</b>	Less than 0.06 mmol/min	More than 20 mins	< 2 mmol/l
3	Between 0.11 and 0.06 mmol/I / min	Average 15 mins	2-3 mmol/min
4	> 0.11 mmol/l / min	Average 7 mins	At least 3 mmol/l



## Libre criteria

- Checking > 8 times Cystic fibrosis di Pregnancy: for a If carers are required to Occupational or psych oth trial Severe hypogly alycaemia Frequent admission oetic ketoa
- Previous self funders who would have met critteria and have shown improvement in HbA1c

# NICE update 2022

 Offer adults with type 1 diabetes a choice of real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM, commonly referred to as 'flash'), based on their individual preferences, needs, characteristics, and the functionality of the devices available.







**NHS Foundation Trust** 



0.0

00.00

03.00

06.00

09.00

12.00

15.00

18.00

21.00

00.00





#### How to measure gucose control: time in range HbA1c TiR Older/High-Risk: Pregnancy: Pregnancy: Type 1<sup>th</sup> & Type 2 Diabetes Type 1 & Type 2 Type 1 Gestational & Type 2 Diabetes Diabetes<sup>†</sup> **Diabetes**§ Target Target Target >140 mg/dL >250 mg/dL >250 mg/dL <5% <10% (7.8 mmol/L) (13.9 mmol/L) (13.9 mmol/L) >140 mg/dL <25% >180 mg/dL <25%\* (7.8 mmol/L) (10.0 mmol/L) >180 mg/dL <50%\* (10.0 mmol/L) Target Range: 63-140 mg/dL Target Range: (3.5-7.8 mmol/L) Target Range: 70-180 mg/dL >70% 63-140 mg/dL >70% (3.9-10.0 mmol/L) (3.5-7.8 mmol/L) Target Range: 70-180 mg/dL >50% (3.9-10.0 mmol/L) <4%\*\* <4%\*\* <63 mg/dL (3.5 mmol/L) <70 mg/dL (3.9 mmol/L) <63 mg/dL (3.5 mmol/L) <70 mg/dL (3.9 mmol/L) <1% <54 mg/dL (3.0 mmol/L) <1% <1% <54 mg/dL (3.0 mmol/L) <54 mg/dL (3.0 mmol/L)

Por age <25 yr., if the A1C goal is 7.5%, then set TIR target to approximately 60%. (See Clinical Applications of Time in Ranges section in the text for additional information regarding target goal setting in pediatric management.) there exists the percentages of time in ranges are based on limited evidence. More research is needed.

§ Percentages of time in ranges have not been included because there is very limited evidence in this area. More research is needed. Please see Pregnancy section in text for more considerations on targets for these groups.

\* Includes percentage of values >250 mg/dL (13.9 mmol/L).

\*\* Includes percentage of values <54 mg/dL (3.0 mmol/L).

## Validation of TiR



## Insulin pumps









# Insulin pumps







	Medtronic 780G	Omnipod dash	T:slim X2
weight	102g	26g	113g
Waterproofing	3.6m for 24 hours	7.6m for 60 mins	1.3m for 30 mins
Capacity	180 or 300 units	200 units	300 units
CGM integration	Guardian link and enlite sensors	X	Dexcom G6
Min basal	0.025 units	0.05 units (0.0 units)	0.1 units
Bolus settings	Min 0.025	0.05,0.1, 0.5 increments	0.05 units



							Brea	kfast				I	Lunch				Dinner			nner					
00 01	02	03 0	14	06	08	0	7 (	8	69	10 1	11	12	13	- 14	4 1	l6 1	16 1	7 1	8	19 :	20	21	22	23	Daily Totals
Wednesday 25/05/2016																<b>31</b> 6.20									Average (0): - Carbs: 31g Inculin: 41.8U Bolus: 15%
Thursday 26/05/2016																	-					-			Average (0): - Carbe: - Inculin: 35.6U Bolue: 0%
Friday 27/05/2016 IHI				Ŧ			<b>u</b> -																		Average (0): - Carbe: - Inculin: 33.00 Bolue: 0%
8aturday 28/06/2018					Τ						-														Average (0): - Carbs: - Inculin: 35.6U Bolus: 0%
Sunday 29/06/2018									44 8.00																Average (0): - Carbs: 40g Insulin: 43.6U Bolus: 18%
Monday 30/05/2016											-									60 10.0					Average (0): - Carbs: 50g Insulin: 45.6U Bolus: 22%
Tuesday 31/05/2016																						-			Average (0): - Carbe: - Inculin: 35.6U Bolus: 0%
Wednesday 01/06/2016 IHI											-					30 6.00		<del>т</del>	ш-	ш- 			<u>5</u> 10.1	0	Average (0): - Carbs: 80g Inculin: 47.5U Bolus: 34%
Thursday 02/06/2016																									Average (0): — Carbs: — Insulin: 35.6U Bolus: 0%
Friday 03/06/2016											-														Average (0): - Carbs: Insulin: 35.60 Bolus: 0%
Saturday 04/08/2016							97 7.40																		Average (0): - Carbs: 37g Insulin: 43.00 Bolus: 17%
Sunday 06/08/2018						40 8.00					-						-							<u>30</u> 6.00	Average (0): - Carbs: 70g Insulin: 49.6U Bolus: 28%
Monday 06/06/2016 IHI									C. A. A. A. S. C.						<b>B-</b>			99 8.80							Average (0): - Carbs: 92g Insulin: 36.3U Bolus: 24%
Tuesday 07/06/2016																	49 8.40								Average (0): — Carbs: 42g Insulin: 44.0U Bolus: 19%
> 7.8mmol/L		00 <sup>°</sup> M	ultiple r	reading	gs (n	nost ex	dreme	shown	)	Ť	î Suş	pend				•	Exerc	lse			0	Partia	l day		() Time change
< 3.9mmol/L	<	<b>_</b> M	anual b	olus o	r bol	ius witi	h corre	ction		9	P Sus	pend t	by Sen	sor		-	Other				144	Pump	rewind		www. Skipped meal



# NICE update 2022

 Offer adults with type 1 diabetes a choice of real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM, commonly referred to as 'flash'), based on their individual preferences, needs, characteristics, and the functionality of the devices available.



## Dexcom G6

- 10 days sensor
- No calibration
- Share with up to 10 followers
- Customisable alarms



## Medtronic guardian connect

- Predictive low alerts
- 6 day sensor life
- Care partners can receive SMS alerts



#### **Eversense XL 90 day implantable glucose sensor**

#### 5-minute Office Procedure of Sensor Insertion

1. 5 to 8 mm incision in upper arm under local anesthetic



2. Sensor inserted with custom inserter







## Hybrid closed loops



**JDRF** 

Information & support Our research Get involved News & media About us For profess

• News • NHS pilot of hybrid closed loop systems successful in improving lives of people with type 1 diabetes

#### NHS pilot of hybrid closed loop systems successful in improving lives of people with type 1 diabetes

Posted on 01 April 2022

# 780G hybrid closed loop



# 780G hybrid closed loop





This report is compatible with the Ambulatory Glucose Profile calculations used by the International Diabetes Center



# Tandem Control IQ

(all adjustments l	Control-IQ	Sleep Activity	Exercise Activity	
🔷 🚺 Delivers	Delivers an automatic correction bolus if sensor glucose is predicted to be above <u>10.0</u> mmol/L	10.0		10.0
B Increases	Increases basal insulin delivery if sensor glucose is predicted to be above <u>8.9</u> mmol/l	8.9	6.7	8.9
🗞 🖪 Maintains	Maintains active Personal Profile settings when sensor glucose is between <u>6.25</u> - <u>8.9</u> mmol/L	6.25 - 8.9	6.25 - 6.7	7.8 - 8.9
Secreases	Decreases basal insulin delivery if sensor glucose is predicted to be below <u>6.25</u> mmol/L	6.25	6.25	7.8
Stops	Stops basal insulin delivery if sensor glucose is predicted to be below <u>3.9</u> mmol/L	3.9	3.9	4.4
	1		mmol/L	

# Omnipod 5 - 2023



Pod and Dexcom G6<sup>®</sup> shown without the necessary adhesive.

# Dual hormone pump



### **Medtronic inpen**

Paired with the Inpen app which is also linked with guardian sensor

Dose advice Dose calculator Dose reminder Carb counting support





## DIY artificial pancreas

📙 LibreView 🗙 🛞 Welco	ome to the AndroidAPS doc 🗙 🕂	
← → C ☆ 🏻 https://androidaps.read	dthedocs.io/en/latest/EN/	☆ \varTheta :
latest Search docs	Docs » Welcome to the AndroidAPS documentation	Î
DOCUMENTATION	Welcome to the AndroidAPS documentation	
⊕ Getting started	AndroidAPS is an open source app for people living with insulin-dependent diabetes that acts as an	
🗄 What do I need	artificial pancreas system (APS) on Google Android smartphones. Main components are different	
How to Install AndroidAPS	openAPS software algorithms which aim to do what a living pancreas does: keeping blood sugar	
🕀 Component Setup	a supported and FDA/CE approved insulin pump and continuous glucose meter.	
Configuration		
AndroidAPS Usage	The app does NOT use self-learning artificial intelligence. Instead, the calculations of AndroidAPS	
🕀 General Hints	are based on the individual dosage algorithm and carbohydrate intake the user manually puts into	
AndroidAPS for children	his treatments profile, but they are verified by the system for safety reasons.	
Troubleshooting	The app is not provided in Google Play - you have to build it from source code by yourself for legal	
⊞ FAQ	reasons.	
Glossary		
Where to go for help	Main components are:	
For Clinicians		
How to help	Watch	
Česky (Czech)		
Deutsch (German)		
☑ Read the Docs v: latest ▼		*
📀 🏉 🧮 💽 💌		▲ 🕨 🔒 .ntl 🔍 23:48 13/01/2020





## Immediate future

- Mobile phone bolusing: Tandem Mobi
- Smaller insulin pumps
- Smaller continuous glucose monitors dexcom G7
- Patch continuous glucose monitors





# Summary

- There has been huge incremental progress in diabetes selfmanagement technologies
- Type 1 diabetes still requires injected insulin Fastidious ongoing self-management without respite
- Innovation needs to combine education with technology even for closed loop
- Evidence needed for all potential user groups assess breadth of biomedical / psychosocial outcomes







#### Living the Dream: Becoming a UK Soccer Star with Type 1 Diabetes

